Kronos Bio has raised $105 million in financing to develop therapies intended to target disease-causing proteins that have so far eluded the best efforts of drug hunters.

The Series A round of funding announced Thursday was led by Vida Ventures and Omega Funds.

Drugs typically work by either binding to a target site on a molecule or blocking it. But San Mateo, CA-based Kronos notes that most of the currently available therapies address the minority of the proteins in the body—those that can be targeted by traditional small molecule drugs. Most of the body’s proteins are considered “undruggable” because they don’t… Read more »